On October 6, 2026, the Food and Drug Administration published Federal Register notice 2026-20427 (91 FR 63563), "Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information," and opened docket FDA-2026-N-10429. The notice sets out approaches FDA is considering for early-phase trials of ibogaine drug products. US biotech sponsors developing ibogaine drug products under an IND, pharmaceutical sponsors of psychedelic drug clinical trials in the United States, CROs and academic centers running federally funded ibogaine trials, and IRBs overseeing early-phase psychedelic drug investigations must review those considerations (dose selection and escalation, care setting, QTc interval monitoring, stopping rules, safety oversight, discharge and follow-up) and submit comments by November 20, 2026, while aligning protocol development with the signaled safety standards, or sponsors whose ibogaine IND protocols do not anticipate the QTc prolongation and arrhythmia risk, nonclinical neurotoxicity, and starting-dose uncertainty risk an FDA clinical hold under 21 CFR 312.42(b)(1)(i) and forgo the chance to shape any later guidance.
FDA will use the docket to decide whether, and how, those elements should weigh in review of ibogaine INDs, before a step such as issuing guidance. HHS-funded trials are expected to study ibogaine in adults with opioid use disorder and adults with post-traumatic stress disorder. Electronic comments close at 11:59 p.m. Eastern Time on November 20, 2026. Late comments will not be considered. The text is Federal Register document 2026-20427 (official PDF).
What does the October 6, 2026 notice change for an ibogaine IND?
FDA has not adopted a binding rule. It has recorded risks it treats as capable of supporting a clinical hold, and the protocol elements on which it wants comment before ibogaine-specific guidance. The notice builds on the July 14, 2026 guidance "Psychedelic Drugs: Considerations for Clinical Investigations" (91 FR 43101) and on Executive Order 14401 of April 18, 2026 (91 FR 21709), which names ibogaine for serious mental illness that persists after standard therapy.
The risks are QTc prolongation with a risk of life-threatening arrhythmia, neurotoxicity in nonclinical studies, and an uncertain human starting dose. FDA has allowed an early-phase IND for noribogaine hydrochloride, an ibogaine derivative, to proceed for alcohol use disorder. The Advanced Research Projects Agency for Health is funding early-phase trials, and the National Institute on Drug Abuse is funding opioid-use-disorder research. Those data are to be made public and may support later IND studies.
| Element | What the notice states |
|---|---|
| Instrument | Notice and request for information, document 2026-20427, 91 FR 63563 |
| Docket | FDA-2026-N-10429, comments by November 20, 2026 |
| Open for comment | Dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, safety oversight |
| Named risks | QTc prolongation and arrhythmia, nonclinical neurotoxicity, uncertain starting dose |
| Hold authority cited | 21 CFR 312.42(b)(1)(i), unreasonable and significant risk of illness or injury |
| First federally supported populations | Adults with opioid use disorder and adults with post-traumatic stress disorder |
Who must act on this docket?
Exposed actors are US biotech sponsors of ibogaine INDs, pharmaceutical sponsors of psychedelic trials in the United States, CROs and academic centers on federally funded ibogaine trials, and IRBs overseeing early-phase psychedelic investigations. A non-US sponsor that files an ibogaine IND with FDA is in the same set. A firm with no US ibogaine or psychedelic IND program has no filing duty: the notice creates no registration or marketing authorization. The contact is Bernard Fischer, Center for Drug Evaluation and Research, [email protected].
What must be filed or rewritten by November 20, 2026?
Comments, data, and information must cite Docket No. FDA-2026-N-10429. Electronic comments, including attachments, are posted unchanged, so manufacturing detail and medical information do not belong in the public text. A confidential submission is paper only: two copies to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, one marked "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION" and one redacted, under 21 CFR 10.20. Paper is timely only if received on or before November 20, 2026.
- Map each live or planned ibogaine protocol to dose selection and escalation, care setting, QTc monitoring, eligibility, stopping rules, safety oversight, and discharge and follow-up.
- Record how the protocol addresses QTc prolongation and arrhythmia, nonclinical neurotoxicity, and the starting dose.
- File public comments or a confidential paper pair by November 20, 2026.
- Brief the IRB on the 21 CFR 312.42(b)(1)(i) framing before the next protocol or consent review.
What is the consequence of leaving the risks unaddressed?
FDA states that the QTc, neurotoxicity, and dose-uncertainty findings can expose subjects to an unreasonable and significant risk of illness or injury under 21 CFR 312.42(b)(1)(i). An IND that does not anticipate that oversight can be placed on clinical hold. Silence on the docket also gives up influence over whether FDA issues guidance. The elements are one possible approach, consistent with the Psychedelics Guidance, not a final standard. Continuous per-jurisdiction monitoring surfaces a Federal Register notice of this kind on its publication date.
Confirm whether any ibogaine or noribogaine protocol or IRB file will be read against this notice. Put November 20, 2026, and the 11:59 p.m. Eastern Time cutoff, on the calendar. Separate a public comment from a confidential paper pair, and brief clinical development and the IRB on the hold points. Obsidian tracks the US clinical-trial instruments that move these IND expectations.
